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interviews (16) were then conducted using a speciﬁc interview guide. Transcripts were 
analysed using thematic analysis to extract concepts related to satisfaction with treat-
ments and to organise them into a model. Items were generated for each concept of 
interest using patients’ words. The resulting test version of the questionnaire was tested 
for relevance and comprehension with 7 patients and revised accordingly; the new 
version was tested on a second set of 5 patients and revised to provide the pilot version. 
A clinician advisory board was involved at each milestone of the questionnaire devel-
opment for validation. RESULTS: The test questionnaire assessed treatment satisfac-
tion through 49 questions and 67 items, organised into 5 sections: treatment efﬁcacy, 
side-effects, convenience and constraints, global impact, and satisfaction. Conceptual 
content of the questionnaire includes comparison to prior state and to expectations, 
satisfaction, acceptability, and intentions. The questionnaire was globally well-
accepted by patients during the tests; few modiﬁcations were made in the structure 
and some items were reformulated. The pilot version (62 items) was ﬁnalised after the 
second round of comprehension tests. CONCLUSIONS: The questionnaire is a unique 
tool to assess treatment satisfaction in patients with severe Crohn’s disease treated by 
anti-TNF. A scoring and validation study is currently being completed before the 
questionnaire can be included in clinical research and epidemiological studies.
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OBJECTIVES: Fibromyalgia (FM), a chronic disorder characterized by persistent, 
widespread pain, has a major impact on health-related quality of life (HRQoL).        
However, little is known about the impact of FM severity on HRQoL in a European 
population. This cross-sectional, observational study evaluated the impact of FM         
severity on HRQoL among French subjects. METHODS: A cross-sectional study 
recruited 88 FM subjects during routine visits to community-based physicians in 
France. Subjects described their pain and HRQoL using the Brief Pain Inventory (BPI),             
Fibromyalgia Impact Questionnaire (FIQ), EuroQol- 5 questionnaire (EQ-5D), Hos-
pital Anxiety and Depression Scale (HADS), and the Medical Outcomes Study (MOS) 
Sleep Scale. FM severity was deﬁned using subjects’ FIQ total scores: 0–39 (mild), 
39–59 (moderate), and 59–100 (severe). Site staff completed case report forms using 
subjects’ medical records. Impact of FM severity on HRQoL was investigated using 
analysis of variance models. RESULTS: The mean age (SD) of subjects was 55.2 (11.8) 
years, and 84% were female. The mean (SD) FIQ total score was 54.8 (17.3), with 
most patients reporting moderate (38%) or severe (43%) FM. Subjects demonstrated 
poor HRQoL scores, which worsened as FM severity worsened. The mean values (SD)       
by FM severity (mild, moderate, severe) were 0.65 (0.18), 0.44 (0.27) and 0.18 (0.33) 
for the EQ-5D; 8.00 (4.08), 9.94 (2.89), and 11.92 (4.42) for HADS anxiety; and 
4.71 (3.04), 6.58 (3.33), and 10.53 (4.02) for HADS depression (p  0.0001 for all 
comparisons). A signiﬁcant association with FM severity was found for the MOS Sleep 
Problems Index (p  0.003), BPI Pain Intensity (p  0.0001), BPI Pain Severity Index 
(p  0.0001), and BPI Pain Interference Index (p  0.0001). CONCLUSIONS: FM 
had a substantial negative impact on HRQoL, which increased as FM severity wors-
ened. These data allow for more precise understanding and quantiﬁcation of mild, 
moderate, and severe FM health states.
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OBJECTIVES: Fatigue is a common symptom of systemic lupus erythematosus (SLE). 
Our objective was to validate the 13-item FACIT-Fatigue scale in SLE patients. 
METHODS: The FACIT-Fatigue scale, Brief Pain Inventory (BPI) and Patient Global 
Assessment Visual Analog Scale (PGA) were completed at baseline and weeks 12, 24, 
and 52 by patients with moderately-severely active extra-renal SLE, participating in a 
rituximab clinical trial (EXPLORER). The SLE Disease Activity Index (SLEDAI) and 
the British Isles Lupus Assessment Group (BILAG) disease activity index were com-
pleted by physicians at the same visits. RESULTS: At baseline, 254 patients completed 
the FACIT-Fatigue. The mean (19.1) was substantially lower than the US average 
(40.1). Cronbach’s alpha was 0.95 at all visits. In cross-sectional analyses, FACIT-
Fatigue differentiated between groups deﬁned by BILAG General domain ratings; 
effect sizes (mean difference/SD) were generally in the 0.5–0.6 range. FACIT-Fatigue 
had moderate-high correlations (r  0.6–0.7) with BPI and PGA, but poor correlations 
with BILAG and SLEDAI total scores (r  0.24–0.29). At weeks 12, 24 and 52, patients 
with improved or unchanged BILAG General status compared to baseline experienced 
a statistically signiﬁcant improvement in FACIT-Fatigue with effect sizes in the range 
of 0.3–0.7. Mean FACIT-Fatigue improvement was higher in patients who improved 
vs. remained unchanged on the BILAG General domain. FACIT-Fatigue scores 
remained stable for patients with worsened BILAG General domain ratings compared 
to baseline (effect sizes generally 0.3). Distribution and anchor-based estimates sug-
gested a minimally important difference (MID) range of 3–6 points. CONCLUSIONS: 
The FACIT-Fatigue is a valid and responsive measure of fatigue in patients with SLE. 
MID in SLE sample is similar to that derived previously in other populations. Since 
few patients experienced worsening of BILAG General status in this study, further 
research is warranted to evaluate the responsiveness of FACIT-Fatigue to worsening 
in this population.
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OBJECTIVES: Patients with chronic pain often suffer from insomnia. It is deﬁned as            
a difﬁculty in initiating or maintaining sleep, which decreases quantity and quality of 
sleep. The combination of chronic pain and insomnia has thus a huge impact of quality 
of life. The aim was to assess the extent of insomnia amongst patients with chronic 
pain and how far an adjustment of medical therapy could improve the well-being of 
these patients. METHODS: In 2008, the Deutsche Gruene Kreuz e. V. in collaboration 
with Johannes Horlemann developed a questionnaire which was distributed in several 
medical sites across Germany. In order to assess the impact of treatment to insomnia 
113 patients with chronic pain were requested to complete the paper questionnaire 
before and after the stable adjustment of pain medication. RESULTS: Most patients  
suffered from pain for several months and received pain medication. Before the initia-
tion of new treatment half of the respondents reported that falling asleep took more 
than one hour and that the total sleep duration was less than 5 hours. In addition, 
90% reported a disturbance of sleep by pain several times per night. As a result, only 
13% of patients felt relaxed and awake in the next morning. However, the difﬁculties 
in falling asleep and maintaining sleep were deﬁnitely diminished after the adjustment 
of pain medication. Beside the reduction of use of sleeping pills three quarter of all 
respondents reported to feel better after sleeping. CONCLUSIONS: The majority of   
chronic pain patients suffer from insomnia. It causes serious difﬁculties in initiating 
or maintaining sleep. The adjustment of pain medication considerably inﬂuenced 
almost all aspects of insomnia. Therefore, it is reasonable to consider a change in 
treatment of chronic pain patients to improve the quality and quantity of sleep and 
thus achieve an increase in quality of life.
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OBJECTIVES: Systemic lupus erythematosus (SLE) has a signiﬁcant impact on patients’ 
health-related quality of life (HRQOL). The purpose of this study was to validate the 
SF-36 for use in moderately-severely active extra-renal SLE patients. METHODS: 
254 SLE patients, participating in a rituximab clinical trial (EXPLORER), completed 
the following scales at baseline, weeks 12, 24, and 52: the SF-36, Brief Pain Inventory 
(BPI), and Patient Global Assessment Visual Analog Scale (PGA). Physicians completed 
the SLE Disease Activity Index (SLEDAI), and the British Isles Lupus Assessment 
Group (BILAG) disease activity index at the same visits. RESULTS: All SF-36 scores 
were 1–2 standard deviations lower than the US general population at baseline. Cron-
bach’s alpha was 0.80 at all visits. In cross-sectional analyses, the SF-36 Physical 
Component Summary (PCS) scores differentiated between groups deﬁned by BILAG 
General and Musculoskeletal domain ratings at most visits. SF-36 scores had moder-
ate-high correlations with BPI and PGA (r  0.40–0.65). Mean changes from baseline 
in the eight SF-36 domain scores, as well as the PCS and Mental Component Summary 
(MCS), were generally in agreement with improved, unchanged and worsened PGA 
scores. Patients with improved or unchanged BILAG General and Musculoskeletal 
status compared to baseline experienced a statistically signiﬁcant improvement in most 
SF-36 PCS scores with effect sizes (mean change / SD) 0.3–0.7. Scores remained stable 
for patients with worsened BILAG ratings (effect sizes generally 0.3). Based on distri-
bution and anchor-based methods the minimally important differences (MID) was 
estimated to be approximately 3–6 points. CONCLUSIONS: The SF-36 is a valid and 
responsive measure of HRQOL in patients with SLE. MIDs in the SLE sample are 
similar to those derived previously in other populations. Since few patients experienced 
worsening of BILAG General and Musculoskeletal domains, further research is war-
ranted to evaluate responsiveness of the SF-36 to worsening in this population.
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OBJECTIVES: According to WHO, obesity is a contemporary disease which threatens 
peoples’ health and health-related quality of life (HRQoL). The prevalence of obesity 
in Greece, in both genders, is among the highest in Europe. Despite the cost of treating 
obesity, research in this area is generally under-funded. The aim of the study was to 
assess the physical and mental health of Greek obese people compared to the general 
(non-obese) population. METHODS: Data was obtained from a representative sample 
(N  981) of the general non-institutional population in Greece. The study was carried 
out in 2006 and participants were face-to-face interviewed. Participants with a BMI 
q30 kgr/m2 (N  161) were compared to the rest of the sample in terms of physical 
and mental health as measured by the SF-12 questionnaire The confounding effect of 
demographic (gender, age, education) and disease-related variables (hypertension, 
hyperlipidaemia, diabetes and other cardiovascular problems) were controlled for 
using ANCOVA. RESULTS: Most obese participants were female (57.8%) and the 
